## Miroslav Malkovsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4816371/publications.pdf

Version: 2024-02-01

123 papers 4,759 citations

108046 37 h-index 64 g-index

126 all docs

126 docs citations

126 times ranked 3010 citing authors

#	Article	IF	CITATIONS
1	Therapeutic Plasma Exchange–Neutralizing Antibody Combination Therapy for Severe Coronavirus Disease 2019. Journal of Infectious Diseases, 2020, 222, 509-510.	1.9	O
2	γδT-cell Receptors Derived from Breast Cancer–Infiltrating T Lymphocytes Mediate Antitumor Reactivity. Cancer Immunology Research, 2020, 8, 530-543.	1.6	42
3	Molecular detection of human T-lymphotropic virus type 1 infection among oncology patients in Germany: A retrospective view. PLoS ONE, 2019, 14, e0217560.	1.1	8
4	Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. Immunology Letters, 2018, 193, 1-10.	1.1	13
5	Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis. Journal of Scleroderma and Related Disorders, 2018, 3, 132-152.	1.0	15
6	BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential. Journal of Investigative Dermatology, 2018, 138, 2489-2491.	0.3	5
7	Partial break in tolerance of NKG2Aâ^'/LIR-1â^' single KIR+ NK cells early in the course of HLA-matched, KIR-mismatched hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 1144-1155.	1.3	3
8	Improved analysis of TCRγδ variable region expression in humans. Journal of Immunological Methods, 2016, 434, 66-72.	0.6	14
9	A Novel Thymoma-Associated Immunodeficiency with Increased Naive T Cells and Reduced CD247 Expression. Journal of Immunology, 2015, 194, 3045-3053.	0.4	32
10	Histological Analysis of γδT Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. Frontiers in Immunology, 2014, 5, 632.	2.2	29
11	A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy. Clinical Genitourinary Cancer, 2013, 11, 407-415.	0.9	11
12	SHIV Antigen Immunization Alters Patterns of Immune Responses to SHIV/Malaria Coinfection and Protects against Life-Threatening SHIV-Related Malaria. Journal of Infectious Diseases, 2013, 208, 260-270.	1.9	5
13	Pilot trial of interleukin-2 and zoledronic acid to augment $\hat{I}^3\hat{I}^*T$ cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunology, Immunotherapy, 2011, 60, 1447-1460.	2.0	127
14	Cutting Edge: TGF- $\hat{l}^21$ and IL-15 Induce FOXP3+ $\hat{l}^3\hat{l}'$ Regulatory T Cells in the Presence of Antigen Stimulation. Journal of Immunology, 2009, 183, 3574-3577.	0.4	147
15	Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating VÎ <sup>3</sup> 9Vδ2 T cells. Aids, 2009, 23, 555-565.	1.0	55
16	CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunology, Immunotherapy, 2008, 57, 1151-1160.	2.0	35
17	$\hat{I}^{3}\hat{I}'T$ cells in rhesus monkeys and their response to simian immunodeficiency virus (SIV) infection. Clinical and Experimental Immunology, 2008, 102, 251-255.	1.1	25
18	Corrigendum to "The combined treatment of human peripheral blood mononuclear cells with thymolymphotropin and interleukin 2 increases PPD-driven T-cell proliferation and IL-2 induced cellular cytotoxicity against HIV-infected cells" [Int. J. Immunopharmacol. 13/8 (1991) 1157–1165]. International Immunopharmacology, 2006, 6, 2069.	1.7	0

#	Article	IF	Citations
19	Interferonâ€Î³â€"Mediated Antiviral Immunity against Orthopoxvirus Infection Is Provided by γδT Cells. Journal of Infectious Diseases, 2006, 193, 1606-1607.	1.9	13
20	Anti–Severe Acute Respiratory Syndrome Coronavirus Immune Responses: The Role Played by Vγ9Vδ2 T Cells. Journal of Infectious Diseases, 2006, 193, 1244-1249.	1.9	78
21	Use of zoledronic acid (ZA) and interleukin-2 (IL-2) to activate and expand VÎ <sup>3</sup> 9VÎ <sup>2</sup> T cells for therapeutic use in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, 2006, 24, 14607-14607.	0.8	0
22	Immune-based therapies for prostate cancer. Immunology Letters, 2005, 96, 3-9.	1.1	22
23	$V\hat{l}^39V\hat{l}^2$ T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy. Immunology Letters, 2005, 100, 14-20.	1.1	35
24	Surgical gloves as a mechanical barrier against human immunodeficiency viruses. British Journal of Surgery, 2005, 75, 171-172.	0.1	77
25	Antiviral reactivities of $\hat{I}^3\hat{I}'$ T cells. Microbes and Infection, 2005, 7, 518-528.	1.0	84
26	Drug-Induced Expansion and Differentiation of $\hat{Vl^3}\hat{Vl}^2$ T Cells In Vivo: The Role of Exogenous IL-2. Journal of Immunology, 2005, 175, 1593-1598.	0.4	76
27	Gamma/delta T cells. Clinical and Applied Immunology Reviews, 2003, 3, 235-245.	0.4	2
28	Innate T cell immunity to HIV-infection. Vaccine, 2002, 20, 1938-1941.	1.7	16
29	Innate T-Cell Immunity in HIV Infections: The Role of Vg9Vd2 T Lymphocytes. Current Molecular Medicine, 2002, 2, 769-781.	0.6	35
30	STAPHYLOCOCCAL SUPERANTIGENS INDUCE LYMPHOTACTIN PRODUCTION BY HUMAN CD4+ AND CD8+ T CELLS. Cytokine, 2001, $16$ , $73$ - $78$ .	1.4	13
31	Differential Susceptibility of NaÃ <sup>-</sup> ve and Activated Human γδT Cells to Activation-Induced Cell Death by T-Cell Receptor Cross-Linking. Molecular Medicine, 2001, 7, 636-643.	1.9	11
32	In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors. Immunology, 2001, 104, 19-27.	2.0	58
33	Natural T Cell Immunity to Intracellular Pathogens and Nonpeptidic Immunoregulatory Drugs. Current Molecular Medicine, 2001, 1, 137-151.	0.6	15
34	Fas-dependent, activation-induced cell death of gammadelta cells. Journal of Biological Regulators and Homeostatic Agents, 2001, 15, 277-85.	0.7	7
35	Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Trends in Immunology, 2000, 21, 129-132.	7.5	141
36	Different Roles of the CD2 and LFA-1 T-Cell Co-receptors for Regulating Cytotoxic, Proliferative, and Cytokine Responses of Human $V\hat{1}^39/V\hat{1}^2$ T Cells. Molecular Medicine, 2000, 6, 196-207.	1.9	22

#	Article	IF	CITATIONS
37	HIV Infections: The Global Epidemiology and Goals for Vaccine Research. Molecular Medicine, 2000, 6, 69-85.	1.9	4
38	Alternative cytotoxic effector mechanisms in infections with immunodeficiency viruses: gammadelta T lymphocytes and natural killer cells. Aids, 2000, 14 Suppl 3, S175-86.	1.0	0
39	In vivo $\hat{I}^{3\hat{l}}$ T Cell Priming to Mycobacterial Antigens by Primary Mycobacterium tuberculosis Infection and Exposure to Nonpeptidic Ligands. Molecular Medicine, 1999, 5, 471-476.	1.9	34
40	In vivo gammadelta T cell priming to mycobacterial antigens by primary Mycobacterium tuberculosis infection and exposure to nonpeptidic ligands. Molecular Medicine, 1999, 5, 471-6.	1.9	13
41	Cyclophilin A Modulates Processing of Human Immunodeficiency Virus Type $1$ p55Gag: Mechanism for Antiviral Effects of Cyclosporin A. Virology, 1998, 245, 197-202.	1.1	56
42	Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. International Immunology, 1998, 10, 609-617.	1.8	98
43	Possible protective and pathogenic roles of gamma delta T lymphocytes in HIV-infections (Review) International Journal of Molecular Medicine, 1998, 1, 409-13.	1.8	11
44	$\hat{I}^{3}\hat{I}$ T cell activation or anergy during infections: the role of nonpeptidic TCR ligands and HLA class I molecules. Journal of Leukocyte Biology, 1997, 62, 287-291.	1.5	27
45	Functional $\hat{I}^3\hat{I}$ T-lymphocyte Defect Associated with Human Immunodeficiency Virus Infections. Molecular Medicine, 1997, 3, 60-71.	1.9	74
46	Restoration of MHC Class I Surface Expression and Endogenous Antigen Presentation by a Molecular Chaperone. Scandinavian Journal of Immunology, 1997, 45, 605-612.	1.3	32
47	Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections. Molecular Medicine, 1997, 3, 60-71.	1.9	42
48	HLA and natural history of HIV infection. Lancet, The, 1996, 348, 141-142.	6.3	21
49	Mechanisms of simian $\hat{I}^3\hat{I}$ T cell cytotoxicity against tumor and immunodeficiency virus-infected cells. Immunology Letters, 1996, 49, 191-196.	1.1	23
50	î³Î´T lymphocyte responses to HIV. Clinical and Experimental Immunology, 1996, 103, 177-184.	1.1	96
51	Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5381-5385.	3.3	85
52	Gamma/delta T lymphocytes in viral Infections. Journal of Leukocyte Biology, 1995, 58, 277-283.	1.5	67
53	Persistent non-B cell lymphocytosis in HIV-infected individuals. Immunology Letters, 1995, 48, 157-158.	1.1	2
54	Stress responses to viral infection. Trends in Microbiology, 1994, 2, 89-91.	3.5	39

#	Article	IF	Citations
55	Antiviral activity of primate $\hat{I}^3\hat{I}$ T lymphocytes isolated by magnetic cell sorting. Journal of Medical Primatology, 1994, 23, 131-135.	0.3	21
56	An Hsp60 related protein is associated with purified HIV and SIV. Journal of Medical Primatology, 1994, 23, 151-154.	0.3	35
57	Cellular immune responses in rhesus macaques infected rectally with low dose simian immunodeficiency virus. Journal of Medical Primatology, 1994, 23, 125-130.	0.3	43
58	CD4-binding compounds: An assay to detect new classes of immunopharmacological agents. International Journal of Immunopharmacology, 1993, 15, 361-369.	1.1	4
59	Pathogenesis of SIV <sub>mac251</sub> after atraumatic inoculation of the rectal mucosa in rhesus monkeys. Journal of Medical Primatology, 1993, 22, 154-161.	0.3	76
60	Pathogenesis of SIVmac251 after atraumatic inoculation of the rectal mucosa in rhesus monkeys. Journal of Medical Primatology, 1993, 22, 154-61.	0.3	63
61	POLYCLONAL ORIGIN OF RHEUMATOID SYNOVIAL T-LYMPHOCYTES. Rheumatology, 1992, 31, 55-57.	0.9	7
62	Modulation of Anti-Tumor Cytotoxicity of Cultured Mast Cells by Metabolic Inhibitors. International Archives of Allergy and Immunology, 1992, 98, 153-157.	0.9	1
63	New hydroxyethylamine HIV protease inhibitors that suppress viral replication. Journal of Medicinal Chemistry, 1992, 35, 3803-3812.	2.9	41
64	The Influence of Adjuvants on the Generation of Autoantibody and Specific Suppression in Rat Erythrocyte-Immunized Mice. Scandinavian Journal of Immunology, 1992, 35, 501-509.	1.3	0
65	Subset heterogeneity among Î <sup>3</sup> δT cells found in peripheral blood during Plasmodium falciparum malaria. Immunology Letters, 1992, 32, 273-274.	1.1	28
66	Are γδT cells important for the elimination of virusâ€infected cells?. Journal of Medical Primatology, 1992, 21, 113-118.	0.3	18
67	Specificity and function of gamma delta T lymphocytes. Folia Biologica, 1992, 38, 293-306.	0.8	3
68	Are gamma delta T cells important for the elimination of virus-infected cells?. Journal of Medical Primatology, 1992, 21, 113-8.	0.3	18
69	MHC-unrestricted cytotoxic and proliferative responses of two distinct human gamma/delta T cell subsets to Daudi cells. Journal of Immunology, 1992, 148, 2315-23.	0.4	49
70	The combined treatment of human peripheral blood mononuclear cells with thymolymphotropin and interleukin 2 increases PPD-driven T-cell proliferation and IL-2 induced cellular cytotoxicity against HIV-infected cells. International Journal of Immunopharmacology, 1991, 13, 1157-1165.	1.1	2
71	Function and Specificity of Human $\hat{V}^{39}/\hat{V}^{2}$ T Lymphocytes. Current Topics in Microbiology and Immunology, 1991, , 179-182.	0.7	2
72	Function and specificity of human V gamma 9/V delta 2 T lymphocytes. Current Topics in Microbiology and Immunology, 1991, 173, 179-82.	0.7	4

#	Article	IF	Citations
73	Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis Journal of Experimental Medicine, 1990, 171, 1567-1579.	4.2	169
74	Recognition by human V gamma $9/V$ delta $2$ T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science, 1990, 250, 1269-1273.	6.0	372
75	Tumour immunotherapy. Current Opinion in Immunology, 1989, 1, 883-890.	2.4	7
76	Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunology Letters, 1989, 23, 103-108.	1.1	96
77	Milan HaÅjek, Lymphokines and Retroviruses. , 1989, , 29-35.		0
78	Infection of B lymphocytes by the human immunodeficiency virus and their susceptibility to cytotoxic cells. European Journal of Immunology, 1988, 18, 1315-1321.	1.6	33
79	INACTIVATION OF HIV BY NONOXYNOL-9. Lancet, The, 1988, 331, 645.	6.3	83
80	A search for retrovirus infection in systemic lupus erythematosus and rheumatoid arthritis Annals of the Rheumatic Diseases, 1988, 47, 206-209.	0.5	31
81	Advances in Human Retroviruses. Advances in Cancer Research, 1988, 51, 307-360.	1.9	12
82	AIDS and the New Viruses., 1988,, 1-24.		0
83	The interleukins in acquired disease. Clinical and Experimental Immunology, 1988, 74, 151-61.	1.1	48
84	NEUTRALISATION OF HIV ISOLATES BY ANTI-IDIOTYPIC ANTIBODIES WHICH MIMIC THE T4 (CD4) EPITOPE: A POTENTIAL AIDS VACCINE. Lancet, The, 1987, 330, 1047-1050.	6.3	68
85	INHIBITION OF HIV REPLICATION IN VITRO BY FUSIDIC ACID. Lancet, The, 1987, 330, 827-828.	6.3	32
86	GROUP SPECIFIC COMPONENT AND HIV INFECTION. Lancet, The, 1987, 329, 1267-1269.	6.3	1
87	ANTIGEN TEST VERSUS REVERSE TRANSCRIPTASE ASSAY FOR DETECTING HIV. Lancet, The, 1987, 330, 1146-1147	<sup>7</sup> .6.3	17
88	Interleukin 2 and its receptor: Structure, function and therapeutic potential. Blood Reviews, 1987, 1, 254-266.	2.8	31
89	Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb. Cellular Immunology, 1987, 110, 282-293.	1.4	27
90	Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature, 1987, 325, 262-265.	13.7	303

#	Article	IF	Citations
91	Generation of lymphokine-activated killer cells does not require DNA synthesis. Immunology, 1987, 60, 471-3.	2.0	13
92	Increased lymphokine activated killer (LAK) activity in the regional lymph nodes of mice following immunization with contact sensitizing agents. Clinical and Experimental Immunology, 1987, 70, 217-21.	1.1	2
93	Lymphokine-activated killer cell activity in rheumatoid arthritis. Clinical and Experimental Immunology, 1987, 68, 535-42.	1.1	8
94	Regulation of accessory cell function by retinoids in murine immune responses. British Journal of Experimental Pathology, 1987, 68, 343-50.	0.4	11
95	ISOLATION OF RETROVIRUSES FROM TWO PATIENTS WITH "COMMON VARIABLE" HYPOGAMMAGLOBULINAEMIA. Lancet, The, 1986, 327, 581-583.	6.3	48
96	REDUCED EXPRESSION OF INTERLEUKIN-2 RECEPTORS IN HYPOGAMMAGLOBULINAEMIA: A POSSIBLE CAUSE OF HIGHER CANCER INCIDENCE. Lancet, The, 1986, 327, 1442-1443.	6.3	13
97	AIDS, PORTUGAL, AND AFRICA. Lancet, The, 1986, 327, 911.	6.3	4
98	Nonspecific inhibitor of DNA synthesis elaborated by T-acceptor cells. Cellular Immunology, 1986, 98, 114-124.	1.4	0
99	T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cellular Immunology, 1986, 103, 476-480.	1.4	50
100	Acquired immunodeficiency with disseminated cryptococcosis Archives of Disease in Childhood, 1986, 61, 289-291.	1.0	11
101	Autologous lymphoid cells exposed to recombinant interleukin-2 in vitro in the absence of antigen can induce the rejection of long-term tolerated skin allografts. Immunology, 1986, 59, 159-61.	2.0	10
102	Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 536-538.	3.3	70
103	The role of dendritic cells in the initiation of immune responses to contact sensitizers. Cellular Immunology, 1985, 94, 427-434.	1.4	142
104	IMPAIRED LYMPHOKINE-ACTIVATED KILLER-CELL ACTIVITY IN PATIENTS WITH HYPOGAMMAGLOBULINAEMIA. Lancet, The, 1985, 326, 340.	6.3	6
105	Augmentation of interleukin-2 production and delayed hypersensitivity in mice infected with Mycobacterium bovis and fed a diet supplemented with vitamin A acetate. Infection and Immunity, 1985, 48, 581-583.	1.0	35
106	In vivo activity of interleukin-2: conversion of a stimulus causing unresponsiveness to a stimulus causing contact hypersensitivity by the injection of interleukin-2. Immunology, 1985, 56, 653-8.	2.0	23
107	Retinoids and in vivo immunity to transplantable tumours: a terra relatively incognita. Trends in Immunology, 1984, 5, 178-180.	7.5	8
108	Is immunological tolerance (non-responsiveness) a consequence of interleukin 2 deficit during the recognition of antigen?. Trends in Immunology, 1984, 5, 340-343.	7.5	66

#	Article	IF	Citations
109	The role of B cell differentiation factors and specific T cell help in the pathogenesis of primary hypogammaglobulinemia. European Journal of Immunology, 1984, 14, 1021-1027.	1.6	19
110	A diet enriched in vitamin A acetate or in vivo administration of interleukin-2 can counteract a tolerogenic stimulus. Proceedings of the Royal Society of London Series B, Containing Papers of A Biological Character, 1984, 220, 439-445.	1.8	33
111	RETINYL ACETATE-MEDIATED AUGMENTATION OF RESISTANCE TO A TRANSPLANTABLE 3-METHYLCHOLANTHRENE-INDUCED FIBROSARCOMA. Transplantation, 1984, 38, 158-160.	0.5	10
112	Enhancement of Contact Sensitization in Mice Fed a Diet Enriched in Vitamin A Acetate. International Archives of Allergy and Immunology, 1984, 75, 120-125.	0.9	31
113	Suppressor cells induced by BCG release non-specific factors in vitro which inhibit DNA synthesis and interleukin-2 production. Immunology, 1984, 51, 65-71.	2.0	33
114	T-cell-mediated enhancement of host-versus-graft reactivity in mice fed a diet enriched in vitamin A acetate. Nature, 1983, 302, 338-340.	13.7	73
115	Enhancement of specific antitumor immunity in mice fed a diet enriched in vitamin A acetate  Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 6322-6326.	3.3	49
116	Nonspecific inhibitor of DNA synthesis elaborated by T acceptor cells. I. Specific hapten- and I-J-driven liberation of an inhibitor of cell proliferation by Lyt-1-2+ cyclophosphamide-sensitive T acceptor cells armed with a product of Lyt-1+2+-specific suppressor cells. Journal of Immunology, 1983, 130, 785-90.	0.4	47
117	Nonspecific inhibitor released by T acceptor cells reduces the production of interleukin-2. Nature, 1982, 300, 652-655.	13.7	76
118	Inverse correlation between cell-surface adhesiveness and malignancy in mouse fibroblastoid cell lines. International Journal of Cancer, 1979, 23, 392-396.	2.3	14
119	MACROPHAGE ELECTROPHORETIC MOBILITY TEST AS A SENSITIVE PROBE OF TRANSPLANTATION IMMUNITY IN MICE. Transplantation, 1979, 28, 121-124.	0.5	3
120	Solubilized tumour-associated antigens of methyl-cholanthrene-induced mouse sarcomas. Comparative studies byin vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests. International Journal of Cancer, 1978, 21, 348-355.	2.3	37
121	The latex particle adherence (LPA) assay for detection of leukocytes with adhesive surface properties. Cellular Immunology, 1978, 35, 217-225.	1.4	9
122	Human urinary bladder carcinoma cell line (T24): immunological studies and search for oncornavirus in T24 cell population and derived clones. Neoplasma, 1978, 25, 513-22.	0.7	3
123	Human urinary bladder carcinoma cell line (T24) in long-term culture: chromosomal studies on a wild population and derived sublines. Neoplasma, 1977, 24, 319-26.	0.7	12